References

1. 1.
   Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association，Steatotic Liver Disease Expert Committee of the Chinese Physicians Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease：A 2018 update［J］.J Clin Hepatol，2018，34（5）：947-957.
2. 2.
   LI J，ZOU B，YEO Y H，et al.Prevalence，incidence，and outcome of non-alcoholic fatty liver disease in Asia，1999-2019：A systematic review and Meta-analysis［J］.Lancet Gastroenterol Hepatol，2019，4（5）：389-398.
3. 3.
   Chinese Society of Hepatology， Chinese Medical Association.Guidelines for the prevention and treatment of metabolic dysfunctionassociated（non-alcoholic）fatty liver disease（Version 2024）［J］.J Prac Hepatol，2024，27（4）：494-510.
4. 4.
   TARGHER G，TILG H，BYRNE C D.Non-alcoholic fatty liver disease：A multisystem disease requiring a multidisciplinary and holistic approach［J］.Lancet Gastroenterol Hepatol，2021，6（7）：578-588.
5. 5.
   LIANG H W，ZHAO W X.Effect of Xiaozhihugan capsule on patients with non-alcoholi steatohepatitis，adiponectin and insulin resistance［J］.Chin J Integr Tradit West Med Liver Dis，2015，25（5）：264-266.
6. 6.
   Digestive Diseases Professional Committee of Chinese Association of Integrated Traditional Chineseand Western Medicine.Consensus on diagnosis and treatment of nonalcoholic fatty liver disease with integrated traditional Chinese and western medicine（2017）［J］.Chin J Integr Trad West Med Dig，2017，25（11）：805-811.
7. 7.
   RINELLA M E，NEUSCHWANDER-TETRI B A，SIDDIQUI M S，et al.AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease［J］.Hepatology（Baltimore，Md.），2023，77（5）：1797-1835.
8. 8.
   Ncd Risk Factor Collaboration（NCD-RISC） .General and abdominal adiposity and hypertension in eight world regions：A pooled analysis of 837 population-based studies with 7·5 million participants［J］.Lancet，2024，404（10455）：851-863.
9. 9.
   RADA P，GONZÁLEZ-RODRÍGUEZ Á，GARCÍA-MONZÓN C，et al.Understanding lipotoxicity in NAFLD pathogenesis：Is CD36 a key driver？［J］.Cell Death Dis，2020，11（9）：802.
10. 10.
    POWELL E E，WONG V W S ，RINELLA M.Non-alcoholic fatty liver disease［J］.Lancet（London，England），2021，397（10290）：2212-2224.
11. 11.
    WANG X J，ZHANG H，LIU S T，et al.Mechanism and combination therapy of berberine in treatment of nonalcoholic fatty liver disease：A review［J］.Chin J Exp Tradit Med Form，2025，31（5）：269-281.
12. 12.
    CAI W，WU S，MING X，et al.IL6 Derived from macrophages under intermittent hypoxia exacerbates NAFLD by promoting ferroptosis via MARCH3-led ubiquitylation of GPX4［J］.Adv Sci（Weinh），2024，11（41）：e2402241.
13. 13.
    MOUNIKA N，MUNGASE S B，VERMA S，et al.Inflammatory protein signatures as predictive disease-specific markers for non-alcoholic steatohepatitis（NASH）［J］.Inflammation，2025，48（1）：25-41.
14. 14.
    ZHANG X，HEREDIA N I，BALAKRISHNAN M，et al.Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults：Results from NHANES 2017-2018［J］.PLoS One，2021，16（6）：e0252164.
15. 15.
    CIARDULLO S，MURACA E，ZERBINI F，et al.Liver stiffness is associated with all-cause mortality in patients with NAFLD：A systematic review and Meta-analysis［J］.Liver Int，2023，43（12）：2604-2610.
16. 16.
    Branch of Hepatobiliary Diseases，China Association of Chinese Medicine.Diagnosis and treatment guideline for Chinese medicine on non-alcoholic steatohepatitis［J］.J Clin Hepatol，2023，39（5）：1041-1048.
17. 17.
    JIA L，ZHANG M，WANG P，et al.Alismatis Rhizoma methanolic extract-Effects on metabolic syndrome and mechanisms of triterpenoids using a metabolomic and lipidomic approach［J］.Front Pharmacol，2022，13：983428.
18. 18.
    HAN X，ZHAO W，ZHOU Q，et al.Procyanidins from hawthorn（Crataegus pinnatifida） alleviate lipid metabolism disorder via inhibiting insulin resistance and oxidative stress，normalizing the gut microbiota structure and intestinal barrier，and further suppressing hepatic inflammation and lipid accumulation［J］.Food Funct，2022，13（14）：7901-7917.
19. 19.
    FAN Z，LIU J，WANG X，et al.Paeoniae Radix Rubra：A review of ethnopharmacology，phytochemistry，pharmacological activities，therapeutic mechanism for blood stasis syndrome，and quality control［J］.Chem Biodivers，2024，21（8）：e202401119.
20. 20.
    CHEN Y，CHEN X，YANG X，et al.Cassiae Semen：A comprehensive review of botany，traditional use，phytochemistry，pharmacology，toxicity，and quality control［J］.J Ethnopharmacol，2023，306：116199.
21. 21.
    NIU Y T，XU H N，ZHANG Y Y，et al.Curcumae Radix：A review of traditional use，phytochemistry，pharmacology，toxicology and quality control［J］.Chem Biodivers，2024，21（5）：e202400098.
22. 22.
    ZHONG Y，LI J，ZHU X，et al.A comprehensive review of bupleuri radix and its bioactive components：With a major focus on treating chronic liver diseases［J］.J Ethnopharmacol，2024，330：118244.
23. 23.
    ZHAO W X，LIU X Y，SHI Y F，et al.Effect of Xiaozhi Hugan capsule on pathology and PPARα gene in rats with non-alcoholic fatty liver disease［J］.J Tradit Chin Med，2007，（11）：1020-1023.
24. 24.
    ZHAO WX，LIU X Y，DUAN R Z，et al.Effect of Xiaozhi Hugan capsule on pathology and CYP2E1 gene in rats with non-alcoholic fatty liver［J］.Chin J Tradit Chin Med Pharm，2007，22（6）：363-366.